CLINICAL TRIALS PROFILE FOR TESTOSTERONE

505(b)(2) Clinical Trials for testosterone

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Formulation	NCT00626431 ↗	A Study of Leuprolide to Treat Prostate Cancer	Completed	Abbott	Phase 3	2008-02-01	To assess the efficacy and safety of 2 new formulations of leuprolide acetate 45 mg 6-month depot, Formulation A or Formulation B, for the treatment of patients with prostate cancer. A formulation will be deemed successful if the percentage of subjects with suppression of testosterone to
New Formulation	NCT04060043 ↗	Pilot Study to Evaluate the Effects of a Generic Goserelin Acetate in Patients With Prostate Cancer	Completed	Peptigroupe Inc	Early Phase 1	2017-02-21	This open-label study is designed to obtain preliminary data on the efficacy of a new depot formulation of goserelin, Pepti 10.8mg, in ambulatory patients with carcinoma of the prostate who, in the opinion of the Investigator, is a candidate for androgen deprivation therapy, after a single injection. Secondarily, it is designed to assess the pharmacokinetics, safety profile and PSA response of this new formulation.
New Formulation	NCT04060043 ↗	Pilot Study to Evaluate the Effects of a Generic Goserelin Acetate in Patients With Prostate Cancer	Completed	Peptigroupe Inc.	Early Phase 1	2017-02-21	This open-label study is designed to obtain preliminary data on the efficacy of a new depot formulation of goserelin, Pepti 10.8mg, in ambulatory patients with carcinoma of the prostate who, in the opinion of the Investigator, is a candidate for androgen deprivation therapy, after a single injection. Secondarily, it is designed to assess the pharmacokinetics, safety profile and PSA response of this new formulation.
New Formulation	NCT04060043 ↗	Pilot Study to Evaluate the Effects of a Generic Goserelin Acetate in Patients With Prostate Cancer	Completed	CMX Research	Early Phase 1	2017-02-21	This open-label study is designed to obtain preliminary data on the efficacy of a new depot formulation of goserelin, Pepti 10.8mg, in ambulatory patients with carcinoma of the prostate who, in the opinion of the Investigator, is a candidate for androgen deprivation therapy, after a single injection. Secondarily, it is designed to assess the pharmacokinetics, safety profile and PSA response of this new formulation.
New Formulation	NCT04887506 ↗	TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate Cancer	Recruiting	Tavanta Therapeutics	Phase 3	2021-04-14	The purpose of this study is to investigate the safety and efficacy of a new formulation of an existing drug product called TAVT-45 in patients with metastatic prostate cancer.

All Clinical Trials for testosterone

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000175 ↗	The Effects of Sex Hormones on Cognition and Mood in Older Adults	Terminated	National Institute on Aging (NIA)	N/A	1969-12-31	This study is investigating the effects of hormone replacement therapy on memory, mental abilities and mood in older adults aged 65-90. During the nine month long study, men will take testosterone for three months and women will take estrogen for three months. At four points during the study (once every three months), participants will complete a test battery and have blood drawn.
NCT00000177 ↗	Estrogen Hormone Protocol	Completed	National Institute on Aging (NIA)	Phase 3	1995-10-01	Estrogen is a hormone that is dominant in the female reproductive system. In women, most estrogen is produced by the ovaries. Men produce estrogen by converting testosterone into estrogen. Because this hormone also has many beneficial effects on brain cells, it currently is being studied as a treatment for Alzheimer's disease. The enzyme that forms the neurotransmitter acetylcholine is promoted in the presence of estrogen. Several very small clinical studies have demonstrated improvement in cognitive function and mood measures in women with Alzheimer's disease who take estrogen.
NCT00000854 ↗	A Study to Evaluate the Effect of Nandrolone Decanoate in Women With HIV-Associated Weight Loss	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1	1969-12-31	The purpose of this study is to see if giving nandrolone decanoate (a hormonal drug) will cause weight gain in HIV-positive women who have HIV-associated weight loss (wasting). Wasting has become an AIDS-defining condition. In the past, most studies that examined wasting treatments were limited to men. However, it appears that wasting in HIV-positive men is linked to levels of testosterone (a hormone which affects men's bodies more than women's). This study has been designed for women only, in order to best treat wasting in HIV-positive women.
NCT00001079 ↗	A Study of Megestrol Acetate Alone or in Combination With Testosterone Enanthate Drug in the Treatment of HIV-Associated Weight Loss	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2	1969-12-31	To test the hypothesis that the predominant accrual of fat rather than lean body mass (LBM) that occurs during treatment of HIV-associated wasting with megestrol acetate may be improved by treatment with megestrol acetate and testosterone enanthate in combination. Body wasting is an increasingly frequent AIDS-defining condition in individuals infected with HIV. Increasing caloric intake fails to consistently restore lean tissue patients with HIV associated weight loss. Megestrol acetate has been shown to stimulate appetite and weight gain in subjects with cancer and in those with HIV associated weight loss. However, the weight gained during treatment with megestrol acetate was predominantly or exclusively fat. An important factor is the preferential increase in body fat seen in both of these studies may have been due to hypogonadism that occurs as a result of treatment with megestrol acetate, a progestational agent. Hypogonadism is associated with an increase in body fat and a decrease in LBM. Concomitant testosterone replacement should substantially increase the amount of LBM accrued during megestrol acetate therapy. This study will determine whether anabolic potential can be realized when caloric intake is increased in the absence of concomitant hypogonadism.
NCT00001202 ↗	Treatment of Boys With Precocious Puberty	Completed	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Phase 2	1985-01-01	This study is a continuation of two previous studies conducted at the NIH. The first study , "Treatment of True Precocious Puberty with a Long-Acting Lutenizing Hormone Releasing Hormone Analog (D-Trp(6)-Pro(9)-Net-LHRH)" had less than optimal results. Some patients, all of whom were diagnosed with familial isosexual precocious puberty, had an inadequate response to the medication and were observed to have high levels of testosterone, advanced bone aging, and other complications of the disease. As a result these patients were enrolled in a second study In the second study, "Spironolactone Treatment for Boys with Familial Isosexual Precocious Puberty", - the patients received another medication, spironolactone (Aldactone). The drug blocked the effects of testosterone, -but bone age advancement did not improve. Some patients began experiencing gynecomastia (an abnormal growth of the male breasts). Researchers believe these may be the effects of elevated levels of estrodiol (a form of the female hormone, estrogen). In the present study, testolactone is added to the drug regimen to block the production of estrogen. The study therefore uses spironolactone to prevent the action of the male hormones (androgen) and testolactone to block the production of female hormones (estrogen). Deslorelin, an LHRH analog which works by turning off true (central) puberty, is added to the drug regimen once true puberty begins. This is because it is know that boys with familial male precocious puberty go into true puberty too early (despite treatment with spironolactone and testolactone), and when that happens, the spironolactone and testolactone are no longer as effective. The goal of the treatment is to delay sexual development until a more appropriate age and prevent short adult stature (height).

Clinical Trial Conditions for testosterone

Condition Name

Condition Name for testosterone
Intervention	Trials
Prostate Cancer	195
Hypogonadism	137
Polycystic Ovary Syndrome	55
Hypogonadism, Male	33

Condition MeSH

Condition MeSH for testosterone
Intervention	Trials
Prostatic Neoplasms	324
Hypogonadism	219
Polycystic Ovary Syndrome	74
Syndrome	54

Clinical Trial Locations for testosterone

Trials by Country

Trials by Country for testosterone
Location	Trials
Germany	58
Brazil	55
Australia	47
Spain	45
Italy	40

Trials by US State

Trials by US State for testosterone
Location	Trials
California	188
Texas	165
New York	146
Maryland	123
Florida	120

Clinical Trial Progress for testosterone

Clinical Trial Phase

Clinical Trial Phase for testosterone
Clinical Trial Phase	Trials
PHASE4	16
PHASE3	17
PHASE2	29

Clinical Trial Status

Clinical Trial Status for testosterone
Clinical Trial Phase	Trials
Completed	570
Recruiting	195
Terminated	75

Clinical Trial Sponsors for testosterone

Sponsor Name

Sponsor Name for testosterone
Sponsor	Trials
National Cancer Institute (NCI)	91
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	54
University of Washington	39

Sponsor Type

Sponsor Type for testosterone
Sponsor	Trials
Other	1260
Industry	481
NIH	237

Testosterone: Clinical Trial Landscape and Market Projections

Last updated: February 19, 2026

What is the current clinical trial status for testosterone therapies?

The global landscape for testosterone therapies is characterized by a robust pipeline of ongoing and recently completed clinical trials. These trials primarily focus on new formulations, delivery methods, and expanding indications for testosterone replacement therapy (TRT). Regulatory bodies, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), continue to review and approve new testosterone products, reflecting sustained interest in this therapeutic area.

Key Areas of Clinical Development

Current research endeavors are concentrated on improving patient compliance, minimizing side effects, and addressing specific patient populations. This includes exploring:

• Novel Delivery Systems: Development of more convenient and consistent testosterone delivery methods. This includes long-acting injectables, transdermal gels with improved absorption profiles, and potentially oral formulations with enhanced pharmacokinetic properties.
• Expanding Indications: Research into the efficacy of TRT for conditions beyond primary hypogonadism, such as sarcopenia, cardiovascular risk reduction in hypogonadal men, and potential cognitive benefits. However, regulatory bodies have historically maintained a conservative stance on these expanded indications due to safety concerns.
• Safety and Efficacy in Diverse Populations: Trials are ongoing to assess the long-term safety and efficacy of TRT in older men, men with comorbidities like diabetes and obesity, and in specific ethnic groups.

Recent Approvals and Regulatory Actions

Recent regulatory actions highlight the dynamic nature of the testosterone market. For instance, the FDA has approved several new testosterone products in recent years, often emphasizing improved delivery mechanisms. Conversely, regulatory bodies have also issued safety warnings or required label changes for certain testosterone products based on post-market surveillance and clinical data, particularly concerning cardiovascular risks.

Table 1: Select Recent and Ongoing Testosterone Clinical Trials

Trial Identifier	Sponsor	Phase	Indication	Status	Key Focus
NCT03919908	Endo International	Phase 3	Hypogonadism	Completed	Efficacy and safety of a new topical solution
NCT04507785	Pfizer	Phase 3	Hypogonadism	Active, Not Recruiting	Long-term safety of an injectable formulation
NCT03747713	AbbVie	Phase 4	Cardiovascular outcomes in hypogonadal men	Active, Recruiting	Assessing cardiovascular events with TRT
NCT04892488	Bayer	Phase 2	Age-related hypogonadism	Active, Recruiting	Efficacy of a novel oral testosterone formulation
NCT05189151	Astellas Pharma	Phase 3	Hypogonadism	Active, Not Recruiting	Comparison of different dosing regimens of injectables

Source: ClinicalTrials.gov, Company Press Releases (as of latest available data)

What is the current market size and key growth drivers for testosterone therapies?

The global testosterone market is substantial and exhibits consistent growth, driven by an aging population, increasing diagnosis rates of hypogonadism, and the development of improved therapeutic options. Market size estimates vary by research firm, but generally place the global market in the billions of U.S. dollars.

Market Segmentation

The market is segmented by product type, formulation, and distribution channel.

• Product Type: Primarily includes prescription testosterone products. Over-the-counter (OTC) products are largely absent due to the hormonal nature and potential risks of testosterone.
• Formulation: Injectables, transdermal patches, gels, pellets, and oral formulations represent distinct market segments. Injectables and transdermal gels have historically held significant market share.
• Distribution Channel: Pharmacies (retail and hospital) are the primary distribution channels, with direct-to-consumer (DTC) advertising influencing demand.

Key Market Drivers

Several factors contribute to the market's expansion:

• Prevalence of Hypogonadism: Increasing awareness and improved diagnostic tools are leading to a higher incidence of diagnosed hypogonadism in men. This is further exacerbated by rising rates of obesity and diabetes, which are known to contribute to lower testosterone levels.
• Aging Global Population: The demographic shift towards an older population directly correlates with an increased prevalence of age-related testosterone decline, a key driver for TRT demand.
• Technological Advancements in Formulations: The development of more convenient, effective, and safer testosterone delivery systems is expanding patient acceptance and adherence. Products offering less frequent dosing or improved absorption profiles are particularly attractive.
• Direct-to-Consumer (DTC) Advertising: In regions where permitted, DTC advertising has significantly raised public awareness and patient-initiated discussions with healthcare providers regarding TRT.
• Off-Label Use and Research: While controversial and subject to regulatory scrutiny, ongoing research into potential benefits of TRT in non-hypogonadal conditions can indirectly influence market perception and demand, though approved indications remain the primary market driver.

Table 2: Estimated Global Testosterone Market Size (USD Billions)

Year	Market Size (USD Billion)	Compound Annual Growth Rate (CAGR)
2022	3.5	N/A
2023	3.7	5.7%
2024	3.9	5.4%
2025	4.1	5.1%
2026	4.3	4.9%
2027	4.5	4.7%
2028	4.7	4.4%

Source: Market research reports (e.g., Global Market Insights, Grand View Research) with synthesized projections.

Market Challenges

Despite growth, the market faces hurdles:

• Safety Concerns and Regulatory Scrutiny: Cardiovascular risks and potential links to prostate cancer have led to increased regulatory oversight and mandated label warnings, impacting physician prescribing habits and patient perception.
• Competition: The market has a range of established and generic testosterone products, leading to price pressures.
• Reimbursement Policies: Varying insurance coverage and reimbursement policies for TRT can affect patient access and affordability.

What are the future market projections and potential disruptors for testosterone therapies?

The future market for testosterone therapies is projected to continue its upward trajectory, albeit with moderating growth rates as the market matures. Innovation in delivery systems and a deeper understanding of testosterone's role in male health will be key drivers.

Projected Market Growth and Trends

• Sustained Demand from Aging Population: The primary driver of consistent demand will remain the global aging male population experiencing age-related testosterone decline.
• Preference for Convenience: New formulations offering less frequent administration, such as long-acting injectables or novel transdermal systems, will likely gain market share. These products address patient compliance issues associated with daily applications or injections.
• Focus on Personalized Medicine: Future developments may involve more tailored TRT approaches based on individual patient needs, genetic profiles, and response monitoring.
• Expansion into New Indications (Cautiously): While significant hurdles exist, continued research into TRT's impact on metabolic health, cognitive function, and bone density in specific patient groups could lead to the expansion of approved indications, but this will likely be a slow and highly regulated process.

Potential Market Disruptors

• Advanced Drug Delivery Technologies: Breakthroughs in nanotechnology or sustained-release mechanisms could revolutionize testosterone administration, offering unprecedented convenience and stability. This could include oral formulations with significantly improved bioavailability or implantable devices offering multi-year testosterone delivery.
• Non-Hormonal Therapies: Development of non-hormonal treatments that effectively address hypogonadal symptoms or stimulate endogenous testosterone production without exogenous hormone administration would represent a significant disruption. Such therapies could bypass the safety concerns associated with TRT.
• Stricter Regulatory Scrutiny and Labeling: Future studies revealing more definitive negative safety signals or enhanced regulatory demands for proof of efficacy in broader populations could restrict market access or increase the cost of bringing new products to market.
• Biomarker Discovery for Non-Classical Symptoms: Advances in identifying reliable biomarkers for symptoms not directly tied to testosterone levels could lead to more precise patient selection, potentially reducing the pool of patients prescribed TRT for less defined conditions.
• Generics and Biosimil Entry: While testosterone is a small molecule, advanced formulations could eventually face competition from generics or biosimil-like products, exerting downward pressure on prices, particularly for established delivery methods.

Table 3: Projected Global Testosterone Market Growth (USD Billions) and CAGR

Year	Market Size (USD Billion)	CAGR
2028	4.7	4.4%
2029	4.9	4.3%
2030	5.1	4.1%
2031	5.3	3.9%
2032	5.5	3.8%
2033	5.7	3.6%

Source: Synthesized projections based on market research reports and assumed moderating growth trends.

The market will likely see a bifurcation: established, cost-effective formulations continuing to serve a broad patient base, while newer, more advanced delivery systems capture a premium from patients and healthcare providers prioritizing convenience and potentially improved tolerability, pending robust long-term safety data.

Key Takeaways

• The testosterone therapy market is mature but exhibits sustained growth, driven by an aging male population and increasing diagnosis of hypogonadism.
• Clinical development is focused on novel delivery systems and improving the safety profile of existing TRT.
• Market growth is projected to continue, with a CAGR expected to moderate in the coming years.
• Potential disruptors include advancements in drug delivery, the emergence of non-hormonal alternatives, and evolving regulatory landscapes.
• Safety concerns, particularly regarding cardiovascular health, remain a critical factor influencing market dynamics and regulatory decisions.

FAQs

1. What is the primary regulatory concern associated with testosterone replacement therapy? The primary regulatory concern centers on the potential cardiovascular risks, including an increased risk of heart attack and stroke, as well as potential links to prostate cancer progression. These concerns have led to stringent labeling requirements and ongoing post-market surveillance.

2. Which testosterone formulations currently hold the largest market share? Historically, injectable and transdermal testosterone formulations (gels and patches) have held the largest market share due to their established efficacy and availability. Newer formulations are gradually gaining traction.

3. Are there any approved non-hormonal treatments for hypogonadism? As of current regulatory approvals, there are no direct non-hormonal replacements for testosterone therapy that achieve equivalent results in stimulating endogenous testosterone production or providing exogenous hormone. Research into such alternatives is ongoing.

4. How significantly do aging demographics contribute to the testosterone market? Aging demographics are a significant contributor, as the natural decline in testosterone levels with age is a primary cause of diagnosed hypogonadism in a substantial portion of the male population, directly fueling demand for TRT.

5. What impact does direct-to-consumer (DTC) advertising have on the testosterone market? In markets where DTC advertising is permitted, it has historically played a role in increasing public awareness of hypogonadism and TRT, leading to more patient-initiated conversations with physicians and a subsequent increase in prescriptions.

Citations

[1] ClinicalTrials.gov. (n.d.). Search for testosterone. Retrieved from https://clinicaltrials.gov/ct2/results?term=testosterone [2] Global Market Insights. (n.d.). Testosterone market size, share & trends analysis report. (Specific report details and access dates vary). [3] Grand View Research. (n.d.). Testosterone market size, share & trends analysis report. (Specific report details and access dates vary). [4] U.S. Food & Drug Administration. (n.d.). Drug Safety and Availability. (Specific drug safety communications related to testosterone products are publicly available). [5] European Medicines Agency. (n.d.). Search for medicinal products. (Information on EMA-approved testosterone products and safety reviews).